Oncolys BioPharma Inc. FY2025 Q3 Earnings Report | IR Tracker

Oncolys BioPharma Inc. FY2025 Q3 Earnings Report | IR Tracker

Financial Highlights

Net Sales: ¥28M
Operating Income: ¥-1.57B
Net Income: ¥-1.62B
EPS: ¥-64.63

Income Statement

Item	Current	Prior	YoY %
Net Sales	¥28M	¥31M	-9.7%
Gross Profit	¥29M	¥31M	-9.0%
SG&A Expenses	¥1.60B	¥1.26B	+26.8%
Operating Income	¥-1.57B	¥-1.23B	-27.7%
Non-operating Income	¥3M	¥6M	-43.1%
Non-operating Expenses	¥47M	¥20M	+138.3%
Ordinary Income	¥-1.61B	¥-1.24B	-29.8%
Profit Before Tax	¥-1.61B	¥-1.24B	-29.8%
Income Tax Expense	¥2M	¥3M	-12.7%
Net Income	¥-1.62B	¥-1.25B	-29.8%
Interest Expense	¥4M	¥3M	+10.1%
Basic EPS	¥-64.63	¥-59.56	-8.5%
Dividend Per Share	¥0.00	¥0.00	-

Balance Sheet

Item	Current End	Prior End	Change
Current Assets	¥2.11B	¥3.10B	¥-986M
Cash and Deposits	¥1.35B	¥2.41B	¥-1.06B
Accounts Receivable	¥30M	-	-
Non-current Assets	¥76M	¥101M	¥-24M
Property, Plant & Equipment	¥3M	-	-

Profitability Ratios

Item	Value
Net Profit Margin	-5775.0%
Gross Profit Margin	102.0%
Current Ratio	662.3%
Quick Ratio	662.3%
Debt-to-Equity Ratio	0.24x
Interest Coverage Ratio	-413.09x
Effective Tax Rate	-0.2%

Year-over-Year Comparison

Item	YoY Change
Net Sales YoY Change	-9.0%

Item	Value
Shares Outstanding (incl. Treasury)	25.87M shares
Treasury Stock	18K shares
Average Shares Outstanding	25.02M shares
Book Value Per Share	¥68.47

Dividend Information

Item	Amount
Q2 Dividend	¥0.00
Year-End Dividend	¥0.00

Full Year Forecast

Item	Forecast
Dividend Per Share Forecast	¥0.00